A detailed history of Ubs Group Ag transactions in Bioventus Inc. stock. As of the latest transaction made, Ubs Group Ag holds 34,376 shares of BVS stock, worth $358,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,376
Previous 12,776 169.07%
Holding current value
$358,885
Previous $73,000 461.64%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.73 - $11.95 $123,768 - $258,119
21,600 Added 169.07%
34,376 $410,000
Q2 2024

Aug 13, 2024

BUY
$3.96 - $6.93 $45,425 - $79,494
11,471 Added 879.0%
12,776 $73,000
Q1 2024

May 13, 2024

SELL
$4.33 - $5.75 $4,637 - $6,158
-1,071 Reduced 45.08%
1,305 $6,000
Q4 2023

Feb 09, 2024

SELL
$2.89 - $5.34 $5,496 - $10,156
-1,902 Reduced 44.46%
2,376 $12,000
Q3 2023

Nov 09, 2023

BUY
$2.8 - $4.94 $6,913 - $12,196
2,469 Added 136.48%
4,278 $14,000
Q2 2023

Aug 11, 2023

SELL
$0.93 - $3.64 $12,943 - $50,661
-13,918 Reduced 88.5%
1,809 $5,000
Q1 2023

May 12, 2023

BUY
$1.07 - $2.95 $3,191 - $8,799
2,983 Added 23.41%
15,727 $16,000
Q4 2022

Feb 08, 2023

BUY
$1.81 - $8.14 $9,723 - $43,728
5,372 Added 72.87%
12,744 $33,000
Q3 2022

Nov 10, 2022

BUY
$6.54 - $9.08 $22,641 - $31,434
3,462 Added 88.54%
7,372 $51,000
Q2 2022

Aug 10, 2022

SELL
$6.82 - $13.82 $8,170 - $16,556
-1,198 Reduced 23.45%
3,910 $27,000
Q1 2022

May 16, 2022

SELL
$11.65 - $15.28 $98,850 - $129,650
-8,485 Reduced 62.42%
5,108 $72,000
Q4 2021

Feb 14, 2022

BUY
$12.37 - $16.77 $168,145 - $227,954
13,593 New
13,593 $197,000
Q3 2021

Nov 15, 2021

SELL
$13.7 - $17.25 $24,016 - $30,239
-1,753 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$13.75 - $18.8 $34,856 - $47,658
-2,535 Reduced 59.12%
1,753 $31,000
Q1 2021

May 12, 2021

BUY
$11.49 - $19.21 $49,269 - $82,372
4,288 New
4,288 $66,000

Others Institutions Holding BVS

About Bioventus Inc.


  • Ticker BVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 61,664,200
  • Market Cap $644M
  • Description
  • Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral ner...
More about BVS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.